Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1-36. (Canceled)
- 37. (Currently amended) An expression vector comprising a nucleotide sequence encoding modified human 5T4 antigen, wherein said modified human 5T4 antigen is modified to differ from a naturally occurring 5T4 antigen and comprises an HLA CTL peptide epitope of 5T4 antigen, and wherein said human 5T4 antigen is capable of inducing an antitumor immunotherapeutic response in a subject.
 - 38. (Canceled)
- 39. (Previously presented) The expression vector according to claim 37, wherein said antitumor immunotherapeutic response is a CTL response or an antibody response.
 - 40. (Canceled)
- 41. (Currently amended) The expression vector according to elaim 40 claim 32, wherein said modified human 5T4 antigen comprises a peptide sequence selected from SEQ ID NOS: 5-17.
- 42. (Currently amended) The expression vector according to elaim 40 claim 37, wherein said modified human 5T4 antigen comprises a peptide sequence selected from SEQ ID NOS: 18-27.
 - 43-47. (Canceled)
- 48. (Currently amended) A pair of vectors for priming and boosting an immune response to human 5T4 antigen in a subject, said pair of vectors comprising a first

Appl. No. 10/774,176 Amdt. dated February 20, 2007 Reply to Office Action of October 12, 2006

vector which is the vector according to claim 37 and a second vector comprising a nucleotide sequence encoding <u>human</u> 5T4 antigen, wherein said second vector is a poxyirus vector.

- 49. (Previously presented) The pair of vectors according to claim 48, wherein said first vector is a poxvirus vector.
- 50. (Previously presented) The pair of vectors according to claim 48, wherein said first vector is MVA.
- 51. (Previously presented) The pair of vectors according to claim 48, wherein said second vector is MVA.
 - 52. (Canceled)
- 53. (Currently amended) The pair of vectors according to elaim 48, wherein said modified human 5T4 antigen encoded by said second vector is modified to differ from a naturally occurring 5T4 antigen and comprises an HLA CTL peptide epitope of 5T4 antigen.